Literature DB >> 8725145

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.

K Schoonjans1, B Staels, J Auwerx.   

Abstract

The three types of peroxisome proliferator-activated receptors (PPAR), termed alpha, delta (or beta), and gamma, belong to the nuclear receptor superfamily. Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional activity of these receptors, only prostaglandin J2 derivatives have been identified as natural ligands of the PPAR gamma subtype that also binds thiazolidinedione antidiabetic agents with high affinity. PPARs heterodimerize with retinoic X receptor (RXR) and alter the transcription of target genes after binding to response elements or PPREs, consisting of a direct repeat of the nuclear receptor hexameric DNA recognition motif (PuGGTCA) spaced by 1 nucleotide (DR-1). Upon activation by fatty acids (FAs) and drugs that affect lipid metabolism, PPARs control the expression of genes implicated in intra- and extracellular lipid metabolism, most notably those involved in peroxisomal beta-oxidation. PPARs partially mediate the inductive effects of fibrates and fatty acids on high density lipoprotein (HDL) cholesterol levels by regulating the transcription of the major HDL apolipoproteins, apoA-I and apoA-II. The hypotriglyceridemic action of fibrates and certain fatty acids also involves PPAR and is constituted of: 1) increased hydrolysis of plasma triglycerides due to induction of LPL and reduction of apoC-III expression; 2) stimulation of cellular fatty acid uptake and conversion to acyl-CoA derivatives due to increased expression of genes for fatty acid transport protein and acyl-CoA synthetase; 3) increased peroxisomal and mitochondrial beta-oxidation; and 4) decreased synthesis of fatty acids and triglycerides and decreased production of very low density lipoprotein (VLDL). Hence, both enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL particles contribute to the hypolipidemic effect of fibrates and fatty acids. Finally, PPARs appear to be involved in differentiation processes because activation of PPAR gamma 2 triggers adipocyte differentiation and stimulates expression of several genes critical to adipogenesis. It is suggested that PPARs are key messengers responsible for the translation of nutritional and pharmacological stimuli into changes in gene expression and differentiation pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725145

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  249 in total

Review 1.  LDL particle size: an important drug target?

Authors:  I Rajman; P I Eacho; P J Chowienczyk; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

Review 3.  Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression.

Authors:  Marc van Bilsen; Ger J van der Vusse; Andries J Gilde; Martijn Lindhout; Karin A J M van der Lee
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

Review 4.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

6.  Role of unfolded protein response in lipogenesis.

Authors:  Ze Zheng; Chunbin Zhang; Kezhong Zhang
Journal:  World J Hepatol       Date:  2010-06-27

7.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

8.  Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

9.  Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

Authors:  Ranjan Chakrabarti; Reeba K Vikramadithyan; Parimal Misra; Jagadheshan Hiriyan; Suryaprakash Raichur; Ravi K Damarla; Cynthia Gershome; Juluri Suresh; Ramanujam Rajagopalan
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

Review 10.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.